IL326140A - Liquid botulinum toxin formulation and use thereof - Google Patents

Liquid botulinum toxin formulation and use thereof

Info

Publication number
IL326140A
IL326140A IL326140A IL32614026A IL326140A IL 326140 A IL326140 A IL 326140A IL 326140 A IL326140 A IL 326140A IL 32614026 A IL32614026 A IL 32614026A IL 326140 A IL326140 A IL 326140A
Authority
IL
Israel
Prior art keywords
botulinum toxin
toxin formulation
liquid botulinum
liquid
formulation
Prior art date
Application number
IL326140A
Other languages
Hebrew (he)
Inventor
Klaus Fink
Harold Victor Taylor
Karl-Heinz Eisele
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Klaus Fink
Harold Victor Taylor
Eisele Karl Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa, Klaus Fink, Harold Victor Taylor, Eisele Karl Heinz filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IL326140A publication Critical patent/IL326140A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
IL326140A 2023-08-10 2024-08-09 Liquid botulinum toxin formulation and use thereof IL326140A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23190937 2023-08-10
PCT/EP2024/072585 WO2025032220A1 (en) 2023-08-10 2024-08-09 Liquid botulinum toxin formulation and use thereof

Publications (1)

Publication Number Publication Date
IL326140A true IL326140A (en) 2026-03-01

Family

ID=87567694

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326140A IL326140A (en) 2023-08-10 2024-08-09 Liquid botulinum toxin formulation and use thereof

Country Status (8)

Country Link
CN (1) CN121693325A (en)
AR (1) AR133528A1 (en)
AU (1) AU2024322347A1 (en)
CO (1) CO2026001534A2 (en)
IL (1) IL326140A (en)
MX (1) MX2026001561A (en)
TW (1) TW202525330A (en)
WO (1) WO2025032220A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
CA2510058C (en) * 2002-12-20 2010-03-16 Botulinum Toxin Research Associates, Inc. Improved pharmaceutical botulinum toxin compositions
BRPI0513850A (en) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa therapeutic composition with a botulically neurotoxin
US9044477B2 (en) 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
PL2271670T3 (en) 2008-03-14 2015-05-29 Allergan Inc Immuno-based botulinum toxin serotype a activity assays
KR20110106346A (en) 2008-12-10 2011-09-28 알러간, 인코포레이티드 Clostridium toxin pharmaceutical composition
HUE037509T2 (en) 2011-09-29 2018-09-28 Cellsnap Llc Compositions and methods for toxigenicity testing
PL3014267T3 (en) 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
KR102272580B1 (en) * 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 Process for preparing a highly pure neurotoxic component of a botulinum toxin and uses thereof
MX395130B (en) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composition comprising botulinum toxin
HUE052023T2 (en) 2016-05-27 2021-04-28 Ipsen Biopharm Ltd A liquid neurotoxin preparation stabilized with tryptophan or tyrosine

Also Published As

Publication number Publication date
MX2026001561A (en) 2026-03-02
AU2024322347A1 (en) 2026-01-29
WO2025032220A1 (en) 2025-02-13
TW202525330A (en) 2025-07-01
AR133528A1 (en) 2025-10-08
CN121693325A (en) 2026-03-17
CO2026001534A2 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
IL315004A (en) Liquid botulinum toxin formulation and use thereof
GB202204964D0 (en) Superpixel generatioion and use
EP4382092A4 (en) Stable liquid formulation containing botulinum toxin
IL314995A (en) Liquid botulinum toxin formulation and its uses
HUE065531T2 (en) Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
GB2611153B (en) Gate driver and display device using the same
GB2578093B (en) Liquid pharmaceutical composition comprising RPL554 and HFA-134A
IL268688B1 (en) Improved use of botulinum neurotoxin in the treatment of sialorrhea
EP4073559A4 (en) DISPLAY DEVICES AND ARTICLES HAVING COLOR-MATCHED DISPLAY AND NON-DISPLAY AREAS
PL3906016T3 (en) Liquid propolis extract, formulation and uses thereof
IL288531A (en) Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same
IL326140A (en) Liquid botulinum toxin formulation and use thereof
EP4083097A4 (en) Composition and display device
IL305789A (en) Usp30 inhibitors and uses thereof
CA3299476A1 (en) Liquid botulinum toxin formulation and use thereof
IL275785A (en) Liquid dispensing arrangements and methods
EP3644971A4 (en) Clostridial neurotoxin formulations and use
IL304528A (en) Liquid formulation of protein and methods of preparing the same
EP4282400A4 (en) Antimicrobial peptide liquid composition and formulation thereof
PL4096097T3 (en) Display and operating device
EP3947323A4 (en) FORMULATIONS COMPATIBLE WITH MYCORRHIZAL AND/OR BACILLUS AMYLOLIC FACIEN LIQUID FERTILIZERS
IL319382A (en) Pharmaceutical composition and use thereof
ZA202212893B (en) Medical liquid dressing and preparation method and application thereof
PL3888634T3 (en) Ophthalmic formulation and its use
EP4209786A4 (en) Fluid device and use thereof